Patrick T. Gunning

University of Toronto — Canada

Medicine · Health Sciences

43h-index5.8kcitations230works5.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cytokine Signaling Pathways and Interactions(80), Protein Degradation and Inhibitors(22), Cancer Mechanisms and Therapy(21), Chronic Myeloid Leukemia Treatments(20), Histone Deacetylase Inhibitors Research(20)

Publications230 total

Acetylation of Axonal G3BP1 through ELP3 Accelerates Axon Regeneration
2025Open Access
Thyroid hormone receptor beta signaling is a targetable driver of prostate cancer growth
Molecular Cancer·2025Open Access
Improved Pharmacokinetic Profiles of HDAC6 Inhibitors via Cap Group Modifications
Journal of Medicinal Chemistry·2025· 1 cited
Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia
Leukemia·2025· 3 citedOpen Access
Monoselective Histone Deacetylase 6 PROTAC Degrader Shows <i>In Vivo</i> Tractability
Journal of Medicinal Chemistry·2025· 13 cited
Thyroid Hormone Receptor Beta Signaling is a Targetable Driver of Prostate Cancer Growth
2025Open Access
Microwave-assisted synthesis of pomalidomide building blocks for rapid PROTAC and molecular glue development
Chemical Communications·2025
Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma
HemaSphere·2024· 4 citedOpen Access
De novo GTP synthesis is a metabolic vulnerability for the interception of brain metastases
Cell Reports Medicine·2024· 6 citedOpen Access
TRSC-04 DE NOVO GTP SYNTHESIS IS A METABOLIC VULNERABILITY FOR THE INTERCEPTION OF BRAIN METASTASES
Neuro-Oncology Advances·2024Open Access
Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia
Journal of Clinical Investigation·2024· 10 citedOpen Access
Next-Generation Tags for Fluorine Nuclear Magnetic Resonance: Designing Amplification of Chemical Shift Sensitivity
Journal of the American Chemical Society·2024· 30 cited
Characterization of conformational states of the homodimeric enzyme fluoroacetate dehalogenase by <sup>19</sup>F–<sup>13</sup>C two-dimensional NMR
RSC Chemical Biology·2024· 5 citedOpen Access
Chemical Proteomics-based Target Prioritization through a Residue Agnostic Ligandability Assessment Platform
2023· 1 citedOpen Access
Discovery of YSR734: A Covalent HDAC Inhibitor with Cellular Activity in Acute Myeloid Leukemia and Duchenne Muscular Dystrophy
Journal of Medicinal Chemistry·2023· 13 citedOpen Access
Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphoma
Research Square (Research Square)·2023· 1 citedOpen Access
Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphoma
2023Open Access
Retraction of “Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies”
ACS Medicinal Chemistry Letters·2023Open Access
Medicinal chemistry advances in targeting class I histone deacetylases
Exploration of Targeted Anti-tumor Therapy·2023· 11 citedOpen Access
INTERCEPTING BRAIN METASTASES THROUGH METABOLIC VULNERABILITIES
Neuro-Oncology Advances·2023Open Access
page 1 of 12Next →

Frequent Co-authors

Brent D. G. Page(14), Richard Moriggl(13), James Turkson(12), Steven Fletcher(11), Elvin D. de Araujo(8), Xiaolei Zhang(7), Peibin Yue(7), Sina Haftchenary(7), Anna Orlova(6), Vijay Shahani(6), Wei Zhao(5), Heidi A. Neubauer(5), Peter Valent(5), Abbarna A. Cumaraswamy(5), Daniel P. Ball(5), Aaron D. Schimmer(5), David A. Rosa(5), Bettina Wingelhofer(4), Carolynn C. Arpin(4), Johan Israelian(4)